Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease

Trial Profile

Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Jan 2019

At a glance

  • Drugs Donanemab (Primary) ; LY 3202626 (Primary)
  • Indications Alzheimer's disease
  • Focus Proof of concept; Therapeutic Use
  • Acronyms TRAILBLAZER-ALZ
  • Sponsors Eli Lilly
  • Most Recent Events

    • 18 Oct 2018 Planned number of patients changed from 375 to 266.
    • 14 Aug 2018 Planned End Date changed from 23 Dec 2020 to 16 Sep 2021.
    • 14 Aug 2018 Planned primary completion date changed from 4 Mar 2020 to 15 Oct 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top